BioProject

In this study, we will investigate the relationships between the mutation sites and patterns, missense mutations or truncation mutations (nonsense mutation, frame-shift variant, splice-site variant, or in-frame deletion), in whole p53 exons in OSCC tissue, and the presence of activating mutations of OSCC oncogenic driver genes (BRAF, CDKN2A, FBXW7, HRAS, NOTCH1, PIK3CA). More...

In this study, we will investigate the relationships between the mutation sites and patterns, missense mutations or truncation mutations (nonsense mutation, frame-shift variant, splice-site variant, or in-frame deletion), in whole p53 exons in OSCC tissue, and the presence of activating mutations of OSCC oncogenic driver genes (BRAF, CDKN2A, FBXW7, HRAS, NOTCH1, PIK3CA). Sixty-seven patients with primary OSCC treated at Dokkyo Medical University Hospital Oral and Maxillofacial Surgery and Ehime University Hospital Dentistry, Oral Surgery and Orthodontics between 2015 and 2020 were subjected to the study. The observation period of the patients was from the sampling date or day of surgery to the final hospital visit. The study was approved by Dokkyo Medical University Hospital Ethics Committee (R-20-19-J) and Ehime University Hospital Ethics Committee (No. 2008016) or by Ehime University Human Genome/Gene Analysis Research Ethics Committee (R2-16). The study was opt-out and there were no patients who requested to be excluded from this study. Less...